



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

(use as many sheets as necessary)

Sheet 1 of 2

| | |
|-------------------------------|-----------------|
| Application Number | 10/606,422 |
| Filing Date | June 26, 2003 |
| First Named Inventor | McComsey et al. |
| Group Art Unit | |
| Examiner Name | |
| Attorney Docket Number | ORT-1222 (DIV) |

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

| Examiner Initials | Cite No. ¹ | Foreign Patent Document | | | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document mm-dd-yyyy | Pages, Columns, Lines, where relevant passages or relevant figures appear | † ² |
|-------------------|-----------------------|-------------------------|---------------------|----------------------|---|---|--|----------------|
| | | Office ³ | Number ⁴ | KndCode ⁵ | | | | |
| | | HU | 9901290 | A | Aventis Pharmaceuticals, Inc. | 11-19-1999 | | |
| | | HU | 9201875 | | Merrell Dow Pharmaceuticals, Inc. | 6-04-1992 | | |
| | | EP | 0503203 | A1 | Merrell Dow Pharmaceuticals, Inc. | 9-16-92 | (=HU 9201875) | |
| | | WO | 92/04371 | A1 | Ferring Peptide Research Partnership KB | 3-19-1992 | | |
| | | WO | 99/42475 | A1 | Ortho-McNeil Pharmaceutical, Inc. | 8-26-1999 | | |
| | | | | | | | | |

| | | | |
|--------------------|---------------|-----------------|---------|
| Examiner Signature | David L. Lutz | Date Considered | 1-18-05 |
|--------------------|---------------|-----------------|---------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Patent and Trademark Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 2

| | |
|------------------------|-----------------|
| Application Number | 10/606,422 |
| Filing Date | June 26, 2003 |
| First Named Inventor | McComsey et al. |
| Group Art Unit | |
| Examiner Name | |
| Attorney Docket Number | ORT-1222 (DIV) |

| OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS | | | |
|---|-----------------------|---|----------------|
| Examiner's Initials* | Cite No. ¹ | Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published | T ² |
| DL | X | Malik, Aamer B., "Thrombin-Induced Endothelial Injury", <i>Seminars in Thrombosis and Hemostasis</i> , Vol. 12, No. 3, 1986 | |
| DL | X | Cindy L.A. JONES, "Response of a human megakaryocytic cell line to thrombin: Increase in intracellular free calcium and mitogen release", <i>Biochimica et Biophysica Acta</i> , 1136 (1992) 272-282 | |
| DL | DL | Ho Sam-ANN, "Structure-Activity Relationships of Pyrazoloquinazolinones as Thrombin Receptor Antagonists", <i>Bioorganic & Medicinal Chemistry Letters</i> 9 (1999) 2073-2078 | |
| DL | DL | Hoekstra, W.J. et al., "Thrombin Receptor (PAR-1) Antagonists. Heterocycle-based peptidomimetics of the SFLR agonist motif", <i>Bioorganic & Medicinal Chemistry Letters</i> , GB, Oxford, Vol. 8, No. 13, 7 July 1998, pgs. 1649-1654 | |
| DL | DL | Bernatowicz E.A., "Development of potent thrombin receptor antagonist peptides", <i>Journal of Medicinal Chemistry</i> , Vol. 39, 1996, pgs. 4879-4887 | |
| DL | X | McComsey, D.F. et al., "Heterocycle-peptide hybrid compounds. Aminotriazole-containing agonists of the thrombin receptor (PAR-1)", <i>Bioorganic & Medicinal Chemistry Letters</i> , GB, Oxford, Vol. 9, No. 10, 17 May 1999, pgs. 1423-1428 | |
| DL | X | B.K. Hwang et al., "Enzyme-Catalyzed Peptide Segment Condensation Using 5 (4H) - Oxazolones as Acyl Donors", <i>J. AM. Chem. Soc.</i> , Vol. 115, No. 17, 1993, pgs. 7912-7913 | |
| DL | X | David T. Hung et al., "Thrombin-Induced Events in Non-Platelet Cells are Mediated by the Unique Proteolytic Mechanism Established for the Closed Platelet Thrombin Receptor", <i>The Journal of Cell Biology</i> , Vol. 116, No. 3, Feb. 1992, pp. 827-832 | |
| DL | X | Kees-Joink et al., "Thrombin Receptor Activation Causes Rapid Neut Cell Rounding and Neut Retraction Independent of Classic Second Messengers", <i>The Journal of Cell Biology</i> , Vol. 118, No. 2, July 1992, pp. 411-419 | |
| DL | DL | Yasuo Sugama et al., "Thrombin-Induced Expression of Endothelial P-Selection and Intercellular Adhesion Molecule-1: A Mechanism for Stabilizing Neutrophil Adhesion", <i>The Journal of Cell Biology</i> , Vol. 119, No. 4, November 1992, pp. 935-944 | |
| DL | DL | Thien-Khai & H. Vu et al., "Molecular Cloning of a Functional Thrombin Receptor Reveals a Novel Proteolytic Mechanism of Receptor Activation", <i>Cell</i> , Vol. 64, March 1991, pp. 1057-1068 | |
| DL | DL | Dimitris N. Tatakis et al., "Thrombin Effects on Osteoblastic Cells- II. Structure-Function Relationships", <i>Biochemical and Biophysical Research Communications</i> , Vol. 174, No. 1, Jan. 1991, pp. 181-188 | |
| DL | X | Jeha M. Hadan et al., "Thrombin Induces Release of Platelet-Derived Growth Factor-Like Molecule(s) by Cultured Human Endothelial Cells", <i>The Journal of Cell Biology</i> , Vol. 103, Sept. 1986, pp. 1129-1133 | |
| DL | X | Michael R. Bevilacqua et al., "Endothelial Leukocyte Adhesion Molecule 1: An Inducible Receptor for Neutrophils related to Complement Regulatory Proteins and Lectins", <i>Science</i> , Vol. 243, March 1989, pp. 1160-1164 | |
| DL | X | D.M. Gorney et al., "Enhancement of Incisional Wound Healing and Neovascularization in Normal Rats by Thrombin and Synthetic Thrombin Receptor Activating Peptides", <i>The American Society for Clinical Investigation Inc.</i> , Vol. 89, May 1992, pp. 1460-1472 | |

| | | | |
|--------------------|--|-----------------|---------|
| Examiner Signature | | Date Considered | 1-18-05 |
|--------------------|--|-----------------|---------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.
DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

